semaglutide and inflammatory bowel disease GLP-1RAs for IBD semaglutide and inflammatory bowel disease

Key Takeaways In the Phase 3 TRIUMPH-1 trial (2026), retatrutide 12 mg produced an average 28.3% body-weight reduction at 80 weeks, with 45.3% of participants losing 30% or more ( New England Journal of Medicine / Eli Lilly, 2026 )

The oral tablet uses a novel absorption enhancer called sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) to facilitate absorption across the gastric mucosa, overcoming the challenge that peptide medications typically face when taken by mouth

A vial containing 5 mg of lyophilized BPC-157 reconstituted in 1 mL of bacteriostatic water yields 5,000 mcg/mL

But what makes semaglutide different, and how does it work

Clinical trials demonstrated that MT-1, combined with UV-B light or sunlight, significantly increased tanning while reducing sunburn cells (1)

Metabolomics by gas chromatographymass spectrometry: combined targeted and untargeted profiling